ASPIC

send to a friend share this

Champalimaud Research Symposium 2024

ASPIC members can request access to a promocode to obtain a discount on registration fee .

 

Champalimaud Centre for the Unknown, Lisbon, Portugal

 

16-18 October, 2024

 

See more informations here: https://symposium.fchampalimaud.science/

Champalimaud Research Symposium 2024

Os membros da ASPIC poderão solicitar acesso a um promocode para obterem um desconto na sua tarifa de registo (mais informação aqui).

 

Champalimaud Centre for the Unknown, Lisbon, Portugal

 

16-18 October, 2024

 

See more informations here: https://symposium.fchampalimaud.science/

Paediatric Cancer Symposium

Main Auditorium of the Champalimaud Foundation in Lisbon, Portugal

 

11 - 12 March 2024

 

See more informations here: https://www.fchampalimaud.org/events/paediatric-cancer-symposium

Paediatric Cancer Symposium

Main Auditorium of the Champalimaud Foundation in Lisbon, Portugal

 

11 - 12 March 2024

 

See more informations here: https://www.fchampalimaud.org/events/paediatric-cancer-symposium

‘Cancro Digestivo - Abordagens Atuais e Futuras Centradas na Prevenção’

Auditório Principal IPO Porto, Porto, Portugal

 

26 February, 2024

 

See more informations here: https://ipoporto.pt/evento/cancro-digestivo-abordagens-atuais-e-futuras-centradas-na-prevencao/

‘Cancro Digestivo - Abordagens Atuais e Futuras Centradas na Prevenção’

Auditório Principal IPO Porto, Porto, Portugal

 

26 February, 2024

 

See more informations here: https://ipoporto.pt/evento/cancro-digestivo-abordagens-atuais-e-futuras-centradas-na-prevencao/

30th Porto Cancer Meeting

i3S, Porto, Portugal

 

09-10 May, 2024

 

See more informations here: https://www.i3s.up.pt/event.php?v=301

30th Porto Cancer Meeting

i3S, Porto, Portugal

 

09-10 May, 2024

 

See more informations here: https://www.i3s.up.pt/event.php?v=301

Study reveals the role of epigenetics in prostate cancer radioresistance

Researchers from the Cancer Biology & Epigenetics Group at the Research Center of IPO Porto, Portugal have revealed a pivotal link between epigenetic regulation and prostate cancer radioresistance. The study, entitled "Epigenetic Regulation of TP53 is Involved in Prostate Cancer Radioresistance and DNA Damage Response Signaling," was recently published in the prestigious journal Signal Transduction and Targeted Therapy.

Estudo revela o papel da epigenética na radioresistência do cancro da próstata

 Investigadores do Grupo de Epigenética e Biologia do Cancro do Centro de Investigação do IPO Porto desvendaram uma ligação fundamental entre a regulação epigenética e a radioresistência no cancro da próstata. O estudo, intitulado "Epigenetic Regulation of TP53 is Involved in Prostate Cancer Radioresistance and DNA Damage Response Signaling", foi recentemente publicado na prestigiada revista Signal Transduction and Targeted Therapy. O cancro da próstata permanece um relevante problema de saúde.